Global Myotonic Dystrophy Drug Market Insights and Forecast to 2027

SKU ID : QYR-18076268 | Publishing Date : 21-Apr-2021 | No. of pages : 119

Detailed TOC of Global Myotonic Dystrophy Drug Market Insights and Forecast to 2027

1 Study Coverage
    1.1 Myotonic Dystrophy Drug Product Introduction
    1.2 Market by Type
        1.2.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Type
        1.4.2 ISIS-DMPKRx
        1.4.3 PRO-135
        1.2.4 SRT-152
        1.2.5 VAL-0411
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Application
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Home Use
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Executive Summary
    2.1 Global Myotonic Dystrophy Drug Sales Estimates and Forecasts 2016-2027
    2.2 Global Myotonic Dystrophy Drug Revenue Estimates and Forecasts 2016-2027
    2.3 Global Myotonic Dystrophy Drug Revenue by Region: 2016 VS 2021 VS 2027
    2.4 Global Top Myotonic Dystrophy Drug Regions by Sales
        2.4.1 Global Top Myotonic Dystrophy Drug Regions by Sales (2016-2021)
        2.4.2 Global Top Myotonic Dystrophy Drug Regions by Sales (2022-2027)
    2.5 Global Top Myotonic Dystrophy Drug Regions by Revenue
        2.5.1 Global Top Myotonic Dystrophy Drug Regions by Revenue (2016-2021)
        2.5.2 Global Top Myotonic Dystrophy Drug Regions by Revenue (2022-2027)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Myotonic Dystrophy Drug Sales by Manufacturers
        3.1.1 Global Top Myotonic Dystrophy Drug Manufacturers by Sales (2016-2021)
        3.1.2 Global Top Myotonic Dystrophy Drug Manufacturers Market Share by Sales (2016-2021)
        3.1.3 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Drug Sales in 2020
    3.2 Global Myotonic Dystrophy Drug Revenue by Manufacturers
        3.2.1 Global Top Myotonic Dystrophy Drug Manufacturers by Revenue (2016-2021)
        3.2.2 Global Top Myotonic Dystrophy Drug Manufacturers Market Share by Revenue (2016-2021)
        3.2.3 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Drug Revenue in 2020
    3.3 Global Myotonic Dystrophy Drug Sales Price by Manufacturers
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Myotonic Dystrophy Drug Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
    4.1 Global Myotonic Dystrophy Drug Sales by Type
        4.1.1 Global Myotonic Dystrophy Drug Historical Sales by Type (2016-2021)
        4.1.2 Global Myotonic Dystrophy Drug Forecasted Sales by Type (2022-2027)
        4.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Type (2016-2027)
    4.2 Global Myotonic Dystrophy Drug Revenue by Type
        4.2.1 Global Myotonic Dystrophy Drug Historical Revenue by Type (2016-2021)
        4.2.2 Global Myotonic Dystrophy Drug Forecasted Revenue by Type (2022-2027)
        4.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2016-2027)
    4.3 Global Myotonic Dystrophy Drug Price by Type
        4.3.1 Global Myotonic Dystrophy Drug Price by Type (2016-2021)
        4.3.2 Global Myotonic Dystrophy Drug Price Forecast by Type (2022-2027)
5 Market Size by Application
    5.1 Global Myotonic Dystrophy Drug Sales by Application
        5.1.1 Global Myotonic Dystrophy Drug Historical Sales by Application (2016-2021)
        5.1.2 Global Myotonic Dystrophy Drug Forecasted Sales by Application (2022-2027)
        5.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Application (2016-2027)
    5.2 Global Myotonic Dystrophy Drug Revenue by Application
        5.2.1 Global Myotonic Dystrophy Drug Historical Revenue by Application (2016-2021)
        5.2.2 Global Myotonic Dystrophy Drug Forecasted Revenue by Application (2022-2027)
        5.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Application (2016-2027)
    5.3 Global Myotonic Dystrophy Drug Price by Application
        5.3.1 Global Myotonic Dystrophy Drug Price by Application (2016-2021)
        5.3.2 Global Myotonic Dystrophy Drug Price Forecast by Application (2022-2027)

6 North America
    6.1 North America Myotonic Dystrophy Drug Market Size by Type
        6.1.1 North America Myotonic Dystrophy Drug Sales by Type (2016-2027)
        6.1.2 North America Myotonic Dystrophy Drug Revenue by Type (2016-2027)
    6.2 North America Myotonic Dystrophy Drug Market Size by Application
        6.2.1 North America Myotonic Dystrophy Drug Sales by Application (2016-2027)
        6.2.2 North America Myotonic Dystrophy Drug Revenue by Application (2016-2027)
    6.3 North America Myotonic Dystrophy Drug Market Size by Country
        6.3.1 North America Myotonic Dystrophy Drug Sales by Country (2016-2027)
        6.3.2 North America Myotonic Dystrophy Drug Revenue by Country (2016-2027)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Myotonic Dystrophy Drug Market Size by Type
        7.1.1 Europe Myotonic Dystrophy Drug Sales by Type (2017-2027)
        7.1.2 Europe Myotonic Dystrophy Drug Revenue by Type (2017-2027)
    7.2 Europe Myotonic Dystrophy Drug Market Size by Application
        7.2.1 Europe Myotonic Dystrophy Drug Sales by Application (2017-2027)
        7.2.2 Europe Myotonic Dystrophy Drug Revenue by Application (2017-2027)
    7.3 Europe Myotonic Dystrophy Drug Market Size by Country
        7.3.1 Europe Myotonic Dystrophy Drug Sales by Country (2017-2027)
        7.3.2 Europe Myotonic Dystrophy Drug Revenue by Country (2017-2027)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Myotonic Dystrophy Drug Market Size by Type
        8.1.1 Asia Pacific Myotonic Dystrophy Drug Sales by Type (2018-2027)
        8.1.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Type (2018-2027)
    8.2 Asia Pacific Myotonic Dystrophy Drug Market Size by Application
        8.2.1 Asia Pacific Myotonic Dystrophy Drug Sales by Application (2018-2027)
        8.2.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Application (2018-2027)
    8.3 Asia Pacific Myotonic Dystrophy Drug Market Size by Region
        8.3.1 Asia Pacific Myotonic Dystrophy Drug Sales by Region (2018-2027)
        8.3.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2018-2027)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Myotonic Dystrophy Drug Market Size by Type
        9.1.1 Latin America Myotonic Dystrophy Drug Sales by Type (2019-2027)
        9.1.2 Latin America Myotonic Dystrophy Drug Revenue by Type (2019-2027)
    9.2 Latin America Myotonic Dystrophy Drug Market Size by Application
        9.2.1 Latin America Myotonic Dystrophy Drug Sales by Application (2019-2027)
        9.2.2 Latin America Myotonic Dystrophy Drug Revenue by Application (2019-2027)
    9.3 Latin America Myotonic Dystrophy Drug Market Size by Country
        9.3.1 Latin America Myotonic Dystrophy Drug Sales by Country (2019-2027)
        9.3.2 Latin America Myotonic Dystrophy Drug Revenue by Country (2019-2027)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
6 Middle East and Africa
    6.1 Middle East and Africa Myotonic Dystrophy Drug Market Size by Type
        6.1.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2016-2027)
        6.1.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Type (2016-2027)
    6.2 Middle East and Africa Myotonic Dystrophy Drug Market Size by Application
        6.2.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Application (2016-2027)
        6.2.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Application (2016-2027)
    6.3 Middle East and Africa Myotonic Dystrophy Drug Market Size by Country
        6.3.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2016-2027)
        6.3.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2016-2027)
        6.3.3 Turkey
        6.3.4 Saudi Arabia
        6.3.5 U.A.E

11 Company Profiles
    11.1 BioMarin Pharmaceutical Inc.
        11.1.1 BioMarin Pharmaceutical Inc. Corporation Information
        11.1.2 BioMarin Pharmaceutical Inc. Overview
        11.1.3 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2016-2021)
        11.1.4 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Product Description
        11.1.5 BioMarin Pharmaceutical Inc. Related Developments
    11.2 F. Hoffmann-La Roche Ltd.
        11.2.1 F. Hoffmann-La Roche Ltd. Corporation Information
        11.2.2 F. Hoffmann-La Roche Ltd. Overview
        11.2.3 F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2016-2021)
        11.2.4 F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Product Description
        11.2.5 F. Hoffmann-La Roche Ltd. Related Developments
    11.3 Genzyme Corporation
        11.3.1 Genzyme Corporation Corporation Information
        11.3.2 Genzyme Corporation Overview
        11.3.3 Genzyme Corporation Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2016-2021)
        11.3.4 Genzyme Corporation Myotonic Dystrophy Drug Product Description
        11.3.5 Genzyme Corporation Related Developments
    11.4 Isis Pharmaceuticals, Inc.
        11.4.1 Isis Pharmaceuticals, Inc. Corporation Information
        11.4.2 Isis Pharmaceuticals, Inc. Overview
        11.4.3 Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2016-2021)
        11.4.4 Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Product Description
        11.4.5 Isis Pharmaceuticals, Inc. Related Developments
    11.5 Marina Biotech, Inc.
        11.5.1 Marina Biotech, Inc. Corporation Information
        11.5.2 Marina Biotech, Inc. Overview
        11.5.3 Marina Biotech, Inc. Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2016-2021)
        11.5.4 Marina Biotech, Inc. Myotonic Dystrophy Drug Product Description
        11.5.5 Marina Biotech, Inc. Related Developments
    11.6 Valentia Biopharma S.L.
        11.6.1 Valentia Biopharma S.L. Corporation Information
        11.6.2 Valentia Biopharma S.L. Overview
        11.6.3 Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2016-2021)
        11.6.4 Valentia Biopharma S.L. Myotonic Dystrophy Drug Product Description
        11.6.5 Valentia Biopharma S.L. Related Developments
    11.1 BioMarin Pharmaceutical Inc.
        11.1.1 BioMarin Pharmaceutical Inc. Corporation Information
        11.1.2 BioMarin Pharmaceutical Inc. Overview
        11.1.3 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2016-2021)
        11.1.4 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Product Description
        11.1.5 BioMarin Pharmaceutical Inc. Related Developments

12 Value Chain and Sales Channels Analysis
    12.1 Myotonic Dystrophy Drug Value Chain Analysis
    12.2 Myotonic Dystrophy Drug Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Myotonic Dystrophy Drug Production Mode & Process
    12.4 Myotonic Dystrophy Drug Sales and Marketing
        12.4.1 Myotonic Dystrophy Drug Sales Channels
        12.4.2 Myotonic Dystrophy Drug Distributors
    12.5 Myotonic Dystrophy Drug Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Myotonic Dystrophy Drug Industry Trends
    13.2 Myotonic Dystrophy Drug Market Drivers
    13.3 Myotonic Dystrophy Drug Market Challenges
    13.4 Myotonic Dystrophy Drug Market Restraints

14 Key Findings in The Global Myotonic Dystrophy Drug Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Figures, Tables and Charts Available in Global Myotonic Dystrophy Drug Market Insights and Forecast to 2027

List of Tables
    Table 1. Global Myotonic Dystrophy Drug Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
    Table 2. Major Manufacturers of ISIS-DMPKRx
    Table 3. Major Manufacturers of PRO-135
    Table 4. Major Manufacturers of SRT-152
    Table 5. Major Manufacturers of VAL-0411
    Table 6. Major Manufacturers of Others
    Table 7. Global Myotonic Dystrophy Drug Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
    Table 8. Global Myotonic Dystrophy Drug Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
    Table 9. Global Myotonic Dystrophy Drug Sales by Region (2016-2021) & (K Pcs)
    Table 10. Global Myotonic Dystrophy Drug Sales Market Share by Region (2016-2021)
    Table 11. Global Myotonic Dystrophy Drug Sales by Region (2016-2021) & (K Pcs)
    Table 12. Global Myotonic Dystrophy Drug Sales Market Share by Region (2022-2027)
    Table 13. Global Myotonic Dystrophy Drug Revenue by Region (2016-2021) & (US$ Million)
    Table 14. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2016-2021)
    Table 15. Global Myotonic Dystrophy Drug Revenue by Region (2022-2027) & (US$ Million)
    Table 16. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2022-2027)
    Table 17. Global Myotonic Dystrophy Drug Sales by Manufacturers (2016-2021) & (K Pcs)
    Table 18. Global Myotonic Dystrophy Drug Sales Share by Manufacturers (2016-2021)
    Table 19. Global Myotonic Dystrophy Drug Revenue by Manufacturers (2016-2021) & (US$ Million)
    Table 20. Global Myotonic Dystrophy Drug Revenue Share by Manufacturers (2016-2021)
    Table 21. Myotonic Dystrophy Drug Price by Manufacturers 2016-2021 (USD/Pcs)
    Table 22. Global Myotonic Dystrophy Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Myotonic Dystrophy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Drug as of 2020)
    Table 24. Myotonic Dystrophy Drug Manufacturing Base Distribution and Headquarters
    Table 25. Manufacturers Myotonic Dystrophy Drug Product Offered
    Table 26. Date of Manufacturers Enter into Myotonic Dystrophy Drug Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Myotonic Dystrophy Drug Sales by Type (2016-2021) & (K Pcs)
    Table 29. Global Myotonic Dystrophy Drug Sales by Type (2022-2027) & (K Pcs)
    Table 30. Global Myotonic Dystrophy Drug Sales Share by Type (2016-2021)
    Table 31. Global Myotonic Dystrophy Drug Sales Share by Type (2022-2027)
    Table 32. Global Myotonic Dystrophy Drug Revenue by Type (2016-2021) & (US$ Million)
    Table 33. Global Myotonic Dystrophy Drug Revenue by Type (2022-2027) & (US$ Million)
    Table 34. Global Myotonic Dystrophy Drug Revenue Share by Type (2016-2021)
    Table 35. Global Myotonic Dystrophy Drug Revenue Share by Type (2022-2027)
    Table 36. Myotonic Dystrophy Drug Price by Type (2016-2021) & (USD/Pcs)
    Table 37. Global Myotonic Dystrophy Drug Price Forecast by Type (2022-2027) & (USD/Pcs)
    Table 38. Global Myotonic Dystrophy Drug Sales by Application (2016-2021) & (K Pcs)
    Table 39. Global Myotonic Dystrophy Drug Sales by Application (2022-2027) & (K Pcs)
    Table 40. Global Myotonic Dystrophy Drug Sales Share by Application (2016-2021)
    Table 41. Global Myotonic Dystrophy Drug Sales Share by Application (2022-2027)
    Table 42. Global Myotonic Dystrophy Drug Revenue by Application (2016-2021) & (US$ Million)
    Table 43. Global Myotonic Dystrophy Drug Revenue by Application (2022-2027) & (US$ Million)
    Table 44. Global Myotonic Dystrophy Drug Revenue Share by Application (2016-2021)
    Table 45. Global Myotonic Dystrophy Drug Revenue Share by Application (2022-2027)
    Table 46. Myotonic Dystrophy Drug Price by Application (2016-2021) & (USD/Pcs)
    Table 47. Global Myotonic Dystrophy Drug Price Forecast by Application (2022-2027) & (USD/Pcs)
    Table 48. North America Myotonic Dystrophy Drug Sales by Type (2016-2021) & (K Pcs)
    Table 49. North America Myotonic Dystrophy Drug Sales by Type (2022-2027) & (K Pcs)
    Table 50. North America Myotonic Dystrophy Drug Revenue by Type (2016-2021) & (US$ Million)
    Table 51. North America Myotonic Dystrophy Drug Revenue by Type (2022-2027) & (US$ Million)
    Table 52. North America Myotonic Dystrophy Drug Sales by Application (2016-2021) & (K Pcs)
    Table 53. North America Myotonic Dystrophy Drug Sales by Application (2022-2027) & (K Pcs)
    Table 54. North America Myotonic Dystrophy Drug Revenue by Application (2016-2021) & (US$ Million)
    Table 55. North America Myotonic Dystrophy Drug Revenue by Application (2022-2027) & (US$ Million)
    Table 56. North America Myotonic Dystrophy Drug Sales by Country (2016-2021) & (K Pcs)
    Table 57. North America Myotonic Dystrophy Drug Sales by Country (2022-2027) & (K Pcs)
    Table 58. North America Myotonic Dystrophy Drug Revenue by Country (2016-2021) & (US$ Million)
    Table 59. North America Myotonic Dystrophy Drug Revenue by Country (2022-2027) & (US$ Million)
    Table 60. Europe Myotonic Dystrophy Drug Sales by Type (2016-2021) & (K Pcs)
    Table 61. Europe Myotonic Dystrophy Drug Sales by Type (2022-2027) & (K Pcs)
    Table 62. Europe Myotonic Dystrophy Drug Revenue by Type (2016-2021) & (US$ Million)
    Table 63. Europe Myotonic Dystrophy Drug Revenue by Type (2022-2027) & (US$ Million)
    Table 64. Europe Myotonic Dystrophy Drug Sales by Application (2016-2021) & (K Pcs)
    Table 65. Europe Myotonic Dystrophy Drug Sales by Application (2022-2027) & (K Pcs)
    Table 66. Europe Myotonic Dystrophy Drug Revenue by Application (2016-2021) & (US$ Million)
    Table 67. Europe Myotonic Dystrophy Drug Revenue by Application (2022-2027) & (US$ Million)
    Table 68. Europe Myotonic Dystrophy Drug Sales by Country (2016-2021) & (K Pcs)
    Table 69. Europe Myotonic Dystrophy Drug Sales by Country (2022-2027) & (K Pcs)
    Table 70. Europe Myotonic Dystrophy Drug Revenue by Country (2016-2021) & (US$ Million)
    Table 71. Europe Myotonic Dystrophy Drug Revenue by Country (2022-2027) & (US$ Million)
    Table 72. Asia Pacific Myotonic Dystrophy Drug Sales by Type (2016-2021) & (K Pcs)
    Table 73. Asia Pacific Myotonic Dystrophy Drug Sales by Type (2022-2027) & (K Pcs)
    Table 74. Asia Pacific Myotonic Dystrophy Drug Revenue by Type (2016-2021) & (US$ Million)
    Table 75. Asia Pacific Myotonic Dystrophy Drug Revenue by Type (2022-2027) & (US$ Million)
    Table 76. Asia Pacific Myotonic Dystrophy Drug Sales by Application (2016-2021) & (K Pcs)
    Table 77. Asia Pacific Myotonic Dystrophy Drug Sales by Application (2022-2027) & (K Pcs)
    Table 78. Asia Pacific Myotonic Dystrophy Drug Revenue by Application (2016-2021) & (US$ Million)
    Table 79. Asia Pacific Myotonic Dystrophy Drug Revenue by Application (2022-2027) & (US$ Million)
    Table 80. Asia Pacific Myotonic Dystrophy Drug Sales by Region (2016-2021) & (K Pcs)
    Table 81. Asia Pacific Myotonic Dystrophy Drug Sales by Region (2022-2027) & (K Pcs)
    Table 82. Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2016-2021) & (US$ Million)
    Table 83. Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2022-2027) & (US$ Million)
    Table 84. Latin America Myotonic Dystrophy Drug Sales by Type (2016-2021) & (K Pcs)
    Table 85. Latin America Myotonic Dystrophy Drug Sales by Type (2022-2027) & (K Pcs)
    Table 86. Latin America Myotonic Dystrophy Drug Revenue by Type (2016-2021) & (US$ Million)
    Table 87. Latin America Myotonic Dystrophy Drug Revenue by Type (2022-2027) & (US$ Million)
    Table 88. Latin America Myotonic Dystrophy Drug Sales by Application (2016-2021) & (K Pcs)
    Table 89. Latin America Myotonic Dystrophy Drug Sales by Application (2022-2027) & (K Pcs)
    Table 90. Latin America Myotonic Dystrophy Drug Revenue by Application (2016-2021) & (US$ Million)
    Table 91. Latin America Myotonic Dystrophy Drug Revenue by Application (2022-2027) & (US$ Million)
    Table 92. Latin America Myotonic Dystrophy Drug Sales by Country (2016-2021) & (K Pcs)
    Table 93. Latin America Myotonic Dystrophy Drug Sales by Country (2022-2027) & (K Pcs)
    Table 94. Latin America Myotonic Dystrophy Drug Revenue by Country (2016-2021) & (US$ Million)
    Table 95. Latin America Myotonic Dystrophy Drug Revenue by Country (2022-2027) & (US$ Million)
    Table 96. Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2016-2021) & (K Pcs)
    Table 97. Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2022-2027) & (K Pcs)
    Table 98. Middle East and Africa Myotonic Dystrophy Drug Revenue by Type (2016-2021) & (US$ Million)
    Table 99. Middle East and Africa Myotonic Dystrophy Drug Revenue by Type (2022-2027) & (US$ Million)
    Table 100. Middle East and Africa Myotonic Dystrophy Drug Sales by Application (2016-2021) & (K Pcs)
    Table 101. Middle East and Africa Myotonic Dystrophy Drug Sales by Application (2022-2027) & (K Pcs)
    Table 102. Middle East and Africa Myotonic Dystrophy Drug Revenue by Application (2016-2021) & (US$ Million)
    Table 103. Middle East and Africa Myotonic Dystrophy Drug Revenue by Application (2022-2027) & (US$ Million)
    Table 104. Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2016-2021) & (K Pcs)
    Table 105. Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2022-2027) & (K Pcs)
    Table 106. Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2016-2021) & (US$ Million)
    Table 107. Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2022-2027) & (US$ Million)
    Table 108. BioMarin Pharmaceutical Inc. Corporation Information
    Table 109. BioMarin Pharmaceutical Inc. Description and Major Businesses
    Table 110. BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
    Table 111. BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Product
    Table 112. BioMarin Pharmaceutical Inc. Recent Developments
    Table 113. F. Hoffmann-La Roche Ltd. Corporation Information
    Table 114. F. Hoffmann-La Roche Ltd. Description and Major Businesses
    Table 115. F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
    Table 116. F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Product
    Table 117. F. Hoffmann-La Roche Ltd. Recent Developments
    Table 118. Genzyme Corporation Corporation Information
    Table 119. Genzyme Corporation Description and Major Businesses
    Table 120. Genzyme Corporation Myotonic Dystrophy Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
    Table 121. Genzyme Corporation Myotonic Dystrophy Drug Product
    Table 122. Genzyme Corporation Recent Developments
    Table 123. Isis Pharmaceuticals, Inc. Corporation Information
    Table 124. Isis Pharmaceuticals, Inc. Description and Major Businesses
    Table 125. Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
    Table 126. Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Product
    Table 127. Isis Pharmaceuticals, Inc. Recent Developments
    Table 128. Marina Biotech, Inc. Corporation Information
    Table 129. Marina Biotech, Inc. Description and Major Businesses
    Table 130. Marina Biotech, Inc. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
    Table 131. Marina Biotech, Inc. Myotonic Dystrophy Drug Product
    Table 132. Marina Biotech, Inc. Recent Developments
    Table 133. Valentia Biopharma S.L. Corporation Information
    Table 134. Valentia Biopharma S.L. Description and Major Businesses
    Table 135. Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
    Table 136. Valentia Biopharma S.L. Myotonic Dystrophy Drug Product
    Table 137. Valentia Biopharma S.L. Recent Developments
    Table 138. Key Raw Materials Lists
    Table 139. Raw Materials Key Suppliers Lists
    Table 140. Myotonic Dystrophy Drug Distributors List
    Table 141. Myotonic Dystrophy Drug Customers List
    Table 142. Myotonic Dystrophy Drug Market Trends
    Table 143. Myotonic Dystrophy Drug Market Drivers
    Table 144. Myotonic Dystrophy Drug Market Challenges
    Table 145. Myotonic Dystrophy Drug Market Restraints
    Table 146. Research Programs/Design for This Report
    Table 147. Key Data Information from Secondary Sources
    Table 148. Key Data Information from Primary Sources
List of Figures
    Figure 1. Myotonic Dystrophy Drug Product Picture
    Figure 2. Global Myotonic Dystrophy Drug Market Share by Type in 2020 & 2027
    Figure 3. ISIS-DMPKRx Product Picture
    Figure 4. PRO-135 Product Picture
    Figure 5. SRT-152 Product Picture
    Figure 6. VAL-0411 Product Picture
    Figure 7. Others Product Picture
    Figure 8. Global Myotonic Dystrophy Drug Sales Market Share by Application in 2020 & 2027
    Figure 9. Hospital
    Figure 10. Clinic
    Figure 11. Home Use
    Figure 12. Others
    Figure 13. Myotonic Dystrophy Drug Report Years Considered
    Figure 14. Global Myotonic Dystrophy Drug Sales 2016-2027 (K Pcs)
    Figure 15. Global Myotonic Dystrophy Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
    Figure 16. Global Myotonic Dystrophy Drug Revenue 2016-2027 (US$ Million)
    Figure 17. Global Myotonic Dystrophy Drug Revenue Market Share by Region in Percentage: 2020 Versus 2027
    Figure 18. Global Myotonic Dystrophy Drug Sales Market Share by Region (2016-2021)
    Figure 19. Global Myotonic Dystrophy Drug Sales Market Share by Region (2022-2027)
    Figure 20. North America Myotonic Dystrophy Drug Sales YoY (2016-2027) & (K Pcs)
    Figure 21. North America Myotonic Dystrophy Drug Revenue YoY (2016-2027) & (US$ Million)
    Figure 22. Europe Myotonic Dystrophy Drug Sales YoY (2016-2027) & (K Pcs)
    Figure 23. Europe Myotonic Dystrophy Drug Revenue YoY (2016-2027) & (US$ Million)
    Figure 24. Asia-Pacific Myotonic Dystrophy Drug Sales YoY (2016-2027) & (K Pcs)
    Figure 25. Asia-Pacific Myotonic Dystrophy Drug Revenue YoY (2016-2027) & (US$ Million)
    Figure 26. Latin America Myotonic Dystrophy Drug Sales YoY (2016-2027) & (K Pcs)
    Figure 27. Latin America Myotonic Dystrophy Drug Revenue YoY (2016-2027) & (US$ Million)
    Figure 28. Middle East & Africa Myotonic Dystrophy Drug Sales YoY (2016-2027) & (K Pcs)
    Figure 29. Middle East & Africa Myotonic Dystrophy Drug Revenue YoY (2016-2027) & (US$ Million)
    Figure 30. The Top 10 and Top 5 Players Market Share by Myotonic Dystrophy Drug Sales in 2020
    Figure 31. The Top 10 and Top 5 Players Market Share by Myotonic Dystrophy Drug Revenue in 2020
    Figure 32. Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
    Figure 33. Global Myotonic Dystrophy Drug Sales Market Share by Type (2016-2027)
    Figure 34. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2016-2027)
    Figure 35. Global Myotonic Dystrophy Drug Sales Market Share by Application (2016-2027)
    Figure 36. Global Myotonic Dystrophy Drug Revenue Market Share by Application (2016-2027)
    Figure 37. North America Myotonic Dystrophy Drug Sales Market Share by Type (2016-2027)
    Figure 38. North America Myotonic Dystrophy Drug Revenue Market Share by Type (2016-2027)
    Figure 39. North America Myotonic Dystrophy Drug Sales Market Share by Application (2016-2027)
    Figure 40. North America Myotonic Dystrophy Drug Revenue Market Share by Application (2016-2027)
    Figure 41. North America Myotonic Dystrophy Drug Sales Share by Country (2016-2027)
    Figure 42. North America Myotonic Dystrophy Drug Revenue Share by Country (2016-2027)
    Figure 43. U.S. Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 44. Canada Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 45. Europe Myotonic Dystrophy Drug Sales Market Share by Type (2016-2027)
    Figure 46. Europe Myotonic Dystrophy Drug Revenue Market Share by Type (2016-2027)
    Figure 47. Europe Myotonic Dystrophy Drug Sales Market Share by Application (2016-2027)
    Figure 48. Europe Myotonic Dystrophy Drug Revenue Market Share by Application (2016-2027)
    Figure 49. Europe Myotonic Dystrophy Drug Sales Share by Country (2016-2027)
    Figure 50. Europe Myotonic Dystrophy Drug Revenue Share by Country (2016-2027)
    Figure 51. Germany Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 52. France Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 53. U.K. Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 54. Italy Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 55. Russia Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 56. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Type (2016-2027)
    Figure 57. Asia Pacific Myotonic Dystrophy Drug Revenue Market Share by Type (2016-2027)
    Figure 58. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Application (2016-2027)
    Figure 59. Asia Pacific Myotonic Dystrophy Drug Revenue Market Share by Application (2016-2027)
    Figure 60. Asia Pacific Myotonic Dystrophy Drug Sales Share by Region (2016-2027)
    Figure 61. Asia Pacific Myotonic Dystrophy Drug Revenue Share by Region (2016-2027)
    Figure 62. China Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 63. Japan Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 64. South Korea Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 65. India Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 66. Australia Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 67. Taiwan Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 68. Indonesia Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 69. Thailand Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 70. Malaysia Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 71. Philippines Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 72. Latin America Myotonic Dystrophy Drug Sales Market Share by Type (2016-2027)
    Figure 73. Latin America Myotonic Dystrophy Drug Revenue Market Share by Type (2016-2027)
    Figure 74. Latin America Myotonic Dystrophy Drug Sales Market Share by Application (2016-2027)
    Figure 75. Latin America Myotonic Dystrophy Drug Revenue Market Share by Application (2016-2027)
    Figure 76. Latin America Myotonic Dystrophy Drug Sales Share by Country (2016-2027)
    Figure 77. Latin America Myotonic Dystrophy Drug Revenue Share by Country (2016-2027)
    Figure 78. Mexico Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 79. Brazil Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 80. Argentina Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 81. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Type (2016-2027)
    Figure 82. Middle East and Africa Myotonic Dystrophy Drug Revenue Market Share by Type (2016-2027)
    Figure 83. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Application (2016-2027)
    Figure 84. Middle East and Africa Myotonic Dystrophy Drug Revenue Market Share by Application (2016-2027)
    Figure 85. Middle East and Africa Myotonic Dystrophy Drug Sales Share by Country (2016-2027)
    Figure 86. Middle East and Africa Myotonic Dystrophy Drug Revenue Share by Country (2016-2027)
    Figure 87. Turkey Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 88. Saudi Arabia Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 89. U.A.E Myotonic Dystrophy Drug Revenue (2016-2027) & (US$ Million)
    Figure 90. Myotonic Dystrophy Drug Value Chain
    Figure 91. Myotonic Dystrophy Drug Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed

Keyplayers in Global Myotonic Dystrophy Drug Market Insights and Forecast to 2027

BioMarin Pharmaceutical Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Isis Pharmaceuticals, Inc.
Marina Biotech, Inc.
Valentia Biopharma S.L.

REQUEST SUMMARY

Request Sample

Pre-order Enquiry

Request Discount

Contact Information

24/7 Research Support

Phone: +1 424 253 0807

[email protected]